Experienced in Hemoglobin SC Disease
Experienced in Hemoglobin SC Disease
University Pediatricians
3901 Beaubien St, 
Detroit, MI 

Overview

Aghiad Chamdin is a Pediatrics specialist and a Pediatric Hematologist Oncology provider in Detroit, Michigan. Dr. Chamdin is rated as an Experienced provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Burkitt Lymphoma, Febrile Neutropenia, Sickle Cell Disease, Hemoglobinopathy, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatrics
Pediatric Hematology Oncology
Hematology
Licenses
Pediatric Hematology-Oncology in MI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

UNIVERSITY PEDIATRICIANS
3901 Beaubien St, Detroit, MI 48201

Additional Areas of Focus

Dr. Chamdin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


21 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 15 Less Clinical Trials
Similar Doctors
Advanced in Hemoglobin SC Disease
Hematology | Oncology
Advanced in Hemoglobin SC Disease
Hematology | Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (34.8 miles away)
Languages Spoken:
English, Urdu
Accepting New Patients
Offers Telehealth

Asra Ahmed is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Hemoglobin SC Disease. Her top areas of expertise are Reticulohistiocytoma, Histiocytosis, Non-Langerhans-Cell Histiocytosis, Rosai-Dorfman Disease, and Bone Marrow Aspiration. Dr. Ahmed is currently accepting new patients.

Advanced in Hemoglobin SC Disease
Hematology Oncology | Hematology | Oncology
Advanced in Hemoglobin SC Disease
Hematology Oncology | Hematology | Oncology

Mclaren Oakland

5680 Bow Pointe Dr, Suite 202, 
Clarkston, MI 
 (30.8 miles away)
Languages Spoken:
English, Greek
Accepting New Patients
Offers Telehealth

Seraphim Pallas is a Hematologist Oncology specialist and a Hematologist in Clarkston, Michigan. Dr. Pallas is rated as a Distinguished provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Protein C Deficiency, Protein S Deficiency, Hereditary Resistance to Anti-Vitamin K, Congenital Antithrombin 3 Deficiency, and Bone Marrow Aspiration. Dr. Pallas is currently accepting new patients.

Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology
Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (34.8 miles away)
Languages Spoken:
English

Sharon Singh is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Singh is rated as an Advanced provider by MediFind in the treatment of Hemoglobin SC Disease. Her top areas of expertise are Thalassemia, Sickle Cell Disease, Hemoglobin SC Disease, and Hemolytic Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chamdin's expertise for a condition
ConditionClose
        View All 25 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile